TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05576961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-af01
Description: Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed bacteria
Description: Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose RX-af01
Description: Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
Study: NCT04983290

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: weancare-domus
Description: Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
Study: NCT04811859

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
Study: NCT06202014

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent radiotherapy with envafolimab and capecitabine
Description: Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
Study: NCT05912257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured perioperative nutrition and exercise
Description: Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Counseling
Description: nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
Study: NCT06135571

Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal surgery
Description: Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
Study: NCT05875142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Digital Tutorial Overview
Description: Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Digital Tutorial Overview
Description: Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Digital Tutorial Overview
Description: Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.
Study: NCT06164483

Intervention type: DIAGNOSTIC_TEST
Intervention: Auditory test
Description: The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR

Intervention type: DIAGNOSTIC_TEST
Intervention: Auditory test
Description: The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR

Intervention type: OTHER
Intervention: CSF sampling
Description: Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
Study: NCT05875142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Training Materials
Description: 10 weeks post-tutorial access to additional digital training materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Training Materials
Description: 10 weeks post-tutorial access to additional digital training materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Feedback and Coaching
Description: 10 weeks post-tutorial access to additional digital training materials and systematic feedback and coaching.
Study: NCT06044584

Intervention type: OTHER
Intervention: No intervention
Description: Observational study with no intervention - Monitoring

Intervention type: OTHER
Intervention: No intervention
Description: Observational study with no intervention - Monitoring
Study: NCT06057649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effleurage Abdominal Massage
Description: perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
Study: NCT05917158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC and JS001
Description: Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
Study: NCT05855421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular Acupuncture
Description: Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
Study: NCT06204250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS1-144
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS1-144
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets.
Study: NCT05340049

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Academic behavioral intervention of teachers
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Academic behavioral intervention of teachers
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Academic behavioral intervention of teachers
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions.
Study: NCT06164483

Intervention type: OTHER
Intervention: CSF sampling
Description: Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
Study: NCT04868578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study treatment PPI
Description: patient take PPI every day during 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: patient take PPI placebo every day during 12 months
Study: NCT06117891

Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.

Intervention type: DRUG
Intervention: Bevacizumab
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.

Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.

Intervention type: DRUG
Intervention: Tremelimumab,
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Study: NCT05487235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: Capsule or tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-1971
Description: Capsule or tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally as tablet or capsule in the acid-reducing agent assessment.
Study: NCT06562946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib
Description: Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib
Description: Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib
Description: Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
Study: NCT05048667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock Wave therapy (SWT)
Description: Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: 5 mL PRP will be administered via intracavernous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham SWT
Description: Sham Shockwave Therapy will be administered in the sham arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: 5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
Study: NCT05522660

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: The following SRS therapy is foreseen: Two fractionation schedules according to radiation oncologist's preferences and patterns of brain metastases: 1 x 18-22 Gy (18-22 Gy) or 5 x 6 Gy (30 Gy).~The following fractionation schedules will be allowed (based on the latest AAPM report on a systematic review and dose response modelling):~* Single fraction SRS (1 x 18-22 Gy) is the preferred schedule for 1-4 brain metastases, each with a longest diameter of ≤20 mm.~* Fractionated SRT (5 x 6 Gy) is preferred for lesions \>20 mm diameter or in case of the presence of 5-10 brain metastases.~* For resection cavity irradiation the same selection criteria may be chosen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients in cohort 1a (Melanoma, treated with ipilimumab plus nivolumab), systemic therapy consists of the combination of ipilimumab plus nivolumab.~* For patients in cohort 1b (Melanoma, treated with anti-PD-1/L1 monotherapy), systemic treatment consists of anti-PD-1/L1 monotherapy.~* For patients in cohort 2a (NSCLC, treated with targeted therapy), systemic therapy consists of targeted therapy (EGFR-, ALK- or ROS1-targeted treatment).~* For patients in cohort 2b (NSCLC, treated with anti-PD-1/L1 therapy with or without chemotherapy), systemic therapy consists of immune-checkpoint inhibition therapy (including an anti-PD-1/L1 compound) with or without chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitor
Description: Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients in cohort 1a (Melanoma, treated with ipilimumab plus nivolumab), systemic therapy consists of the combination of ipilimumab plus nivolumab.~* For patients in cohort 1b (Melanoma, treated with anti-PD-1/L1 monotherapy), systemic treatment consists of anti-PD-1/L1 monotherapy.~* For patients in cohort 2a (NSCLC, treated with targeted therapy), systemic therapy consists of targeted therapy (EGFR-, ALK- or ROS1-targeted treatment).~* For patients in cohort 2b (NSCLC, treated with anti-PD-1/L1 therapy with or without chemotherapy), systemic therapy consists of immune-checkpoint inhibition therapy (including an anti-PD-1/L1 compound) with or without chemotherapy.
Study: NCT04986917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hernia repair surgery using the Su2ura® approximation device
Description: . The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Tests
Description: All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Pregnancy Test
Description: Urine pregnancy test will be performed during the screening visit (for WOCBP).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal Ultrasound imaging
Description: All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EuraHS-QoL
Description: patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analouge Scale (VAS)
Description: A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical evaluation for hernia recurrence and clinical bulging
Description: The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity.
Study: NCT05444231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training A
Description: Interventions may include education, exercises, and/or strategies to support brain health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Training B
Description: Interventions may include education, exercises, and/or strategies to support brain health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Training C
Description: Interventions may include education, exercises, and/or strategies to support brain health
Study: NCT04579224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study: NCT05089812

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Third-molar extraction using platelet-rich fibrin as a filling of the alveolus
Description: see above

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third-molar extraction using platelet-rich fibrin as a filling of the alveolus
Description: see above
Study: NCT05906342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% fat meal
Description: Provided to participants once throughout duration of study, contains 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% fat meal
Description: Provided to participants once throughout duration of study, contains 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60% fat meal
Description: Provided to participants once throughout duration of study, contains 60% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% fat meal
Description: Provided to participants once throughout duration of study, contains 80% fat
Study: NCT04579224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab Govitecan
Description: Receive IV
Study: NCT06155279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
Description: The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery.
Study: NCT05290766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of four dental implants
Description: placement of four dental implants according to the  All on four concept

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of two dental implants
Description: placement of two dental implants according to  All on two concepts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular full arch prosthesis
Description: loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular full arch prosthesis
Description: loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
Study: NCT05147350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306 (oral PKMYT1 inhibitor)
Description: RP-6306 (Oral) in combination with FOLFIRI (IV)